Biophytis � Sarconeos (BIO101)

Biophytis is developing a portfolio of programs that target biological resilience pathways that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Sarconeos (BIO101) has been tested for safety and efficacy in a global, randomized, multicenter, double-blinded, placebo-controlled Phase 2 clinical trial (SARA-INT) with sarcopenic patients at risk of mobility disability. Top Line Results (TLRs) released end of July 2021, showed that Sarconeos (BIO101) at the highest dose (350 mg bid) showed a clinically meaningful improvement of 0.10 m/s in the 400-meter walk test (400MWT), the primary endpoint of the study. In addition, Sarconeos (BIO101) showed a very good safety profile at the doses of 175 mg bid and of 350 mg bid with no Serious Adverse Events (AE) related to the product. Biophytis is now committed to progress Sarconeos (BIO101) into phase 3 either alone or through partnerships with pharmaceutical companies. Sarconeos (BIO101) will be the only drug candidate in Phase 3 currently being tested for sarcopenia.